| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $3.4M | +17.5% | -6.0% |
| SG&A Expense | $6.4M | -7.7% | +191.6% |
| Operating Income | -$9.8M | +0.3% | -69.3% |
| Net Income | -$9.0M | -1.8% | -77.2% |
| EPS (Basic) | -$0.22 | -4.8% | +54.2% |
| EPS (Diluted) | -$0.22 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $94.5M | -3.3% | +39.3% |
| Accounts Receivable | $7K | -78.8% | +75.0% |
| Current Assets | $95.1M | -3.5% | +39.1% |
| Total Assets | $96.0M | -3.6% | +39.6% |
| Current Liabilities | $2.0M | +12.4% | -55.5% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.4M | — | +26.9% |
| Investing Cash Flow | $0 | — | — |
| Financing Cash Flow | $0 | — | -100.0% |
| +54.2% |
| $2.4M |
| +5.7% |
| -47.1% |
| Stockholders' Equity | $93.6M | -3.8% | +45.8% |